Table III.
Progression-free survival with respect to treatment and vimentin immunoreactivity.
| Comparison | Vimentin immunoreactivity=0 | Vimentin immunoreactivity >0 | Log-rank P-value | HRa (95% CI): Vimentin immunoreactivity >0 vs. 0 | Wald chi-square: P-valuea |
|---|---|---|---|---|---|
| EB arm: Median PFS in months | 4.0 | 3.0 | 0.4594 | 1.336 (0.616–2.899) | 0.4630 |
| PGB arm: Median PFS in months | 5.7 | 6.9 | 0.0811 | 0.598 (0.334–1.072) | 0.0845 |
| Log-rank P-value | 0.1809 | 0.0021 | – | – | – |
| HRa (95% CI): PGB vs. EB | 0.703 (0.417–1.183) | 0.276 (0.115–0.659) | – | – | – |
| Wald chi-square P-valuea | 0.1841 | 0.0038 | – | – | – |
a
Univariate Cox model. PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; EB, erlotinib/bevacizumab; PGB, cisplatin/gemcitabine/bevacizumab.